Biotron (ASX:BIT) — Material Events
ASX:BIT · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Biotron Advances HBV Drug and Secures Sedarex in $2.5M Capital RaiseMedium
Biotron acquires Sedarex, raises $2.5M, advances HBV drug BIT-HBV001 with promising preclinical results
29 Jan 2026
·Quarterly Activities and Cash Flow Report
·85
Biotron Acquires Sedarex to Advance Safer Anaesthetic with $2.5M RaiseHigh
Biotron to acquire Sedarex and raise $2.5M to advance next-gen anaesthetic SedRx
15 Oct 2025
·Acquisition and Capital Raising
·85
Biotron’s BIT-HBV001 Outperforms Tenofovir in Preclinical Hepatitis B StudiesMedium
Biotron's HBV drug BIT-HBV001 shows superior antiviral activity and synergy with Tenofovir; patent filed
14 Nov 2025
·Program Update
·85
Biotron Accelerates Hepatitis B Research, Eyes Sedarex Acquisition with $2.5M RaiseMedium
Biotron advances Hepatitis B R&D, appoints director, announces Sedarex acquisition and $2.5M capital raise
30 Oct 2025
·Quarterly Activities and Cash Flow Report
·85
Biotron’s BIT-HBV001 Targets Hepatitis Delta, Broadening Treatment HorizonsMedium
Biotron's BIT-HBV001 shows activity against Hepatitis Delta Virus; Sedarex acquisition integrated and regulatory progress underway
18 Mar 2026
·Program Update
·80
Biotron Clears First Regulatory Hurdle for SedRx AnaestheticMedium
Biotron meets first Sedarex milestone with EMA regulatory feedback
13 July 2026
·Milestone Achievement Announcement
·75
Biotron Advances HBV Drug, Completes Sedarex Acquisition Amid Funding ChallengesMedium
Biotron reports half-year loss, completes Sedarex acquisition, advances HBV drug, raises $2.5M capital
26 Feb 2026
·Half Year Report
·75
Biotron Raises $1.5M in Rights Issue to Advance Sedarex Acquisition and Drug PipelineMedium
Biotron launches $1.5M rights issue to fund Sedarex acquisition and drug development
18 Nov 2025
·Prospectus
·75
Biotron Secures $1.52M in Rights Issue, Advances with Sedarex AcquisitionMedium
Biotron closes fully subscribed rights issue raising $1.52M, completes Sedarex acquisition
30 Jan 2026
·Capital Raising
·75
Biotron Secures $1M to Advance Sedarex Acquisition and Antiviral PipelineMedium
Biotron completes $1M placement to fund Sedarex acquisition and product development
2 Dec 2025
·Capital Raising
·75
Biotron Raises $645K in Rights Issue, Eyes HBV Drug ProgressMedium
Biotron closes rights issue raising $645K with shortfall commitment from Peak Asset Management
19 Dec 2025
·Capital Raising
·70
Biotron Narrows Loss, Raises $1.27M, Pushes Ahead with Antiviral PipelineMedium
Biotron posts reduced loss, raises $1.27M, advances antiviral drug programs
27 Aug 2025
·Annual Report and Appendix 4E Preliminary Final Report
·70
Biotron Advances Hepatitis B Drug After $1.27M Capital RaiseMedium
Biotron raises $1.27M, advances Hepatitis B drug animal study, appoints new director
29 July 2025
·Quarterly Activities and Cash Flow Report
·70
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Biotron (ASX:BIT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026